Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

NCT03379857 | Active Not Recruiting

• 1 other identifier: 6640
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 6

Brief Summary

Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects. There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

Conditions

Stroke; Cannabis Use

Outcome Measures

Primary Outcomes (2)

• Evaluation Cannabis use

  12 months

• Reversible vasoconstriction on medical imaging of intracranial arteries at different moment

  medical imaging of intracranial arteries will show new stenoses (topography, number, evolution), and new ischemic or cerebral haemorrhagic lesions

  12 months.

Study Arms (1)

Cannabis User

OTHER

Other: Drug urinal test

Interventions

Drug urinal test OTHER

Non Applicable

Also known as: Magnetic Resonance Imaging, Computerized Tomography Scan, Transcranial Doppler Ultrasound

Cannabis User

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subject between 18 and 45 years old
• Stroke confirmed by medical imaging
• Written informed consent (subject, nearby or emergency procedure)
• Subject affiliate to a local healthcare insurance office
• For female of childbearing potential, an adequate contraceptive measur

You may not qualify if:

• Subject with psychiatric disorder, unable to understand the study or cooperate
• Subject under guardianship or forfeiture of liberty
• Pregnant or breastfeeding woman

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (6)

Chu Jean Minjoz

Besançon, 25030, France

Location

Unite Neuro-Vasculaire

Colmar, 68024, France

Location

Chu Bocage

Dijon, 21079, France

Location

C.H. G. Muller

Mulhouse, 68070, France

Location

Hopital Central

Nancy, 54035, France

Location

Les Hôpitaux Universitaires de Strasbourg

Strasbourg, 67098, France

Location

MeSH Terms

Conditions

Stroke

Interventions

Magnetic Resonance Spectroscopy; Ultrasonography, Doppler, Transcranial

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Spectrum Analysis; Chemistry Techniques, Analytical; Investigative Techniques; Echoencephalography; Neuroradiography; Neuroimaging; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis; Radiography; Ultrasonography; Ultrasonography, Doppler; Diagnostic Techniques, Neurological

Study Officials

• Valérie WOLFF, MD

  Hôpitaux Universitaires de Strasbourg

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Cannabis User

Study Record Dates

• First Submitted: September 29, 2017
• First Posted: December 20, 2017
• Study Start: January 11, 2018
• Primary Completion: January 11, 2025
• Study Completion: January 11, 2025
• Last Updated: February 20, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (6)